{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:12:06Z","timestamp":1793679126103,"version":"4.5.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K01532X\/1"],"award-info":[{"award-number":["MR\/K01532X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/P025064\/1"],"award-info":[{"award-number":["MR\/P025064\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"Oxford NIHR Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR Imperial College NHS Trust Biomedical Research Centre"},{"name":"NIHR Research Professorship"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jhep.2020.05.029","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T11:27:12Z","timestamp":1590492432000},"page":"794-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9390-9990","authenticated-orcid":false,"given":"Dung","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7778-7137","authenticated-orcid":false,"given":"David","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7334-3803","authenticated-orcid":false,"given":"Alun","family":"Vaughan-Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7143-7168","authenticated-orcid":false,"given":"Andrea","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-0831","authenticated-orcid":false,"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2020.05.029_bib1","series-title":"Global Hepatitis Report, 2017","year":"2017"},{"issue":"1","key":"10.1016\/j.jhep.2020.05.029_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"10179","key":"10.1016\/j.jhep.2020.05.029_bib3","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jhep.2020.05.029_bib4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12879-019-3923-5","article-title":"Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort","volume":"19","author":"Laurain","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.jhep.2020.05.029_bib5","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.29258","article-title":"Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study","volume":"66","author":"Saxena","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2020.05.029_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jvh.12609","article-title":"Community-based real-world treatment outcomes of sofosbuvir\/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States","volume":"24","author":"Wong","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.jhep.2020.05.029_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.05.029_bib8","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jhep.2020.05.029_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-Free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2020.05.029_bib10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2020.05.029_bib11","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2020.05.029_bib12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jhep.2016.11.022","article-title":"Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir\/sofosbuvir","volume":"66","author":"Wyles","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2020.05.029_bib13","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in\u00a0vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jhep.2020.05.029_bib14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/jvh.12795","article-title":"Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4","volume":"25","author":"Camus","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"issue":"5","key":"10.1016\/j.jhep.2020.05.029_bib15","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.29837","article-title":"Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors","volume":"69","author":"Smith","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2020.05.029_bib16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jhep.2017.11.037","article-title":"Eliminating hepatitis C within low-income countries - the need to cure genotypes 4, 5, 6","volume":"68","author":"Asselah","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2020.05.029_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40265-016-0685-x","article-title":"Genotype 3 infection: the last stand of hepatitis C virus","volume":"77","author":"Chan","year":"2017","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jhep.2020.05.029_bib18","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1-7 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2020.05.029_bib19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hep.30225","article-title":"Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r","volume":"69","author":"Fourati","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2020.05.029_bib20","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jhep.2017.06.035","article-title":"Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries","volume":"67","author":"da Silva Filipe","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2020.05.029_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2468-1253(18)30382-0","article-title":"Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial","volume":"4","author":"Gupta","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2020.05.029_bib22","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/S0618-8278(19)30199-9","article-title":"Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes: implications for global elimination","volume":"70","author":"Childs","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2020.05.029_bib23","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1053\/j.gastro.2018.02.017","article-title":"HCV genotype 6a escape from and resistance to velpatasvir, pibrentasvir, and sofosbuvir in robust infectious cell culture models","volume":"154","author":"Pham","year":"2018","journal-title":"Gastroenterology"},{"issue":"Pt 8","key":"10.1016\/j.jhep.2020.05.029_bib24","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1099\/vir.0.048835-0","article-title":"Characterization of full-length hepatitis C virus sequences for subtypes 1e, 1h and 1l, and a novel variant revealed Cameroon as an area in origin for genotype 1","volume":"94","author":"Li","year":"2013","journal-title":"J\u00a0Gen Virol"},{"issue":"6","key":"10.1016\/j.jhep.2020.05.029_bib25","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jhep.2019.07.025","article-title":"Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: implications for global elimination of hepatitis C","volume":"71","author":"Childs","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2020.05.029_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/(SICI)1096-9071(199602)48:2<191::AID-JMV12>3.0.CO;2-I","article-title":"Genotype determination of hepatitis C virus from northern India: identification of a new subtype","volume":"48","author":"Panigrahi","year":"1996","journal-title":"J\u00a0Med Virol"},{"issue":"4","key":"10.1016\/j.jhep.2020.05.029_bib27","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/j.1365-2893.2010.01379.x","article-title":"Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy","volume":"18","author":"Kumthip","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.05.029_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.virusres.2014.11.003","article-title":"Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy","volume":"196","author":"Chusri","year":"2015","journal-title":"Virus Res"},{"issue":"12","key":"10.1016\/j.jhep.2020.05.029_bib29","doi-asserted-by":"crossref","first-page":"E30","DOI":"10.1111\/j.1469-0691.2011.03665.x","article-title":"High genetic diversity including potential new subtypes of hepatitis C virus genotype 6 in Lao People's Democratic Republic","volume":"17","author":"Hubschen","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"Pt 11","key":"10.1016\/j.jhep.2020.05.029_bib30","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1099\/vir.0.81334-0","article-title":"Development and characterization of a transient-replication assay for the genotype 2a hepatitis C virus subgenomic replicon","volume":"86","author":"Targett-Adams","year":"2005","journal-title":"J\u00a0Gen Virol"},{"issue":"5","key":"10.1016\/j.jhep.2020.05.029_bib31","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1128\/AAC.02932-15","article-title":"Enhancement of the replication of hepatitis C virus replicons of genotypes 1 to 4 by manipulation of CpG and UpA dinucleotide frequencies and use of cell lines expressing SECL14L2 for antiviral resistance testing","volume":"60","author":"Witteveldt","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jhep.2020.05.029_bib32","doi-asserted-by":"crossref","first-page":"e0134395","DOI":"10.1371\/journal.pone.0134395","article-title":"Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients","volume":"10","author":"Dietz","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jhep.2020.05.029_bib33","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.28706","article-title":"Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection","volume":"64","author":"Abergel","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2020.05.029_bib34","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2018.11.004","volume":"70","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2020.05.029_bib35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2020.05.029_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(18)30341-8","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2020.05.029_bib37","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1053\/j.gastro.2015.07.063","article-title":"Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection","volume":"149","author":"Gane","year":"2015","journal-title":"Gastroenterology"},{"issue":"27","key":"10.1016\/j.jhep.2020.05.029_bib38","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jhep.2020.05.029_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/apt.15043","article-title":"Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir","volume":"49","author":"Nguyen","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jhep.2020.05.029_bib40","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3851\/IMP3217","article-title":"Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam","volume":"23","author":"Thu Thuy","year":"2018","journal-title":"Antivir Ther"},{"issue":"12","key":"10.1016\/j.jhep.2020.05.029_bib41","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/ajg.2017.399","article-title":"Open label study of 8 vs. 12 weeks of ledipasvir\/sofosbuvir in genotype 6 treatment naive or experienced patients","volume":"112","author":"Nguyen","year":"2017","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820303482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820303482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:41:18Z","timestamp":1759174878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820303482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0168827820303482"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.05.029","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}